Home › Funds › SILVERARC CAPITAL MANAGEMENT, LLC › KNSA
SILVERARC CAPITAL MANAGEMENT, LLC position in KNSA
KINIKSA PHARMACEUTICALS INTL · Health Care
SILVERARC CAPITAL MANAGEMENT, LLC reported holding 75,697 shares of KNSA (KINIKSA PHARMACEUTICALS INTL) in its Q3 2026 13F filing — a position valued at US$5.6M, representing 0.72% of its reported portfolio and ranking #36 among its reported holdings. SILVERARC CAPITAL MANAGEMENT, LLC has disclosed KNSA holdings in 4 of the last 7 reported quarters, going back to Q1 2025.
Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR
How SILVERARC CAPITAL MANAGEMENT, LLC's KNSA position evolved
SILVERARC CAPITAL MANAGEMENT, LLC first disclosed a stake in KNSA in Q1 2025 at 88,215 shares (US$2.0M). The position peaked in Q3 2026 at 75,697 shares, worth US$5.6M. Across 4 filings, SILVERARC CAPITAL MANAGEMENT, LLC increased the stake 1 time(s), trimmed it 1 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 75,697 shares valued at US$5.6M.
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q1 2025 | 88.22K | $1.96M | New |
| Q2 2025 | 75.96K | $2.10M | Reduce |
| Q3 2025 | 88.91K | $3.45M | Add |
| Q3 2026 | 75.70K | $5.65M | New |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About KNSA and 13F data
KNSA (KINIKSA PHARMACEUTICALS INTL) is a Health Care company. 51 other funds we track also report a position in KNSA — the largest reported positions include Rubric Capital Management LP (US$255.8M), BAKER BROS. ADVISORS LP (US$181.3M), TANG CAPITAL MANAGEMENT LLC (US$144.5M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding KNSA
- Rubric Capital Management LP 4.00M sh · $255.79M · Q2 2026
- BAKER BROS. ADVISORS LP 2.83M sh · $181.28M · Q2 2026
- TANG CAPITAL MANAGEMENT LLC 2.26M sh · $144.52M · Q2 2026
- Spruce Street Capital LP 918.07K sh · $58.71M · Q2 2026
- RICE HALL JAMES & ASSOCIATES, LLC 624.93K sh · $39.96M · Q2 2026
- ORBIMED ADVISORS LLC 420.60K sh · $26.90M · Q2 2026
- Penn Capital Management Company, LLC 347.66K sh · $25.97M · Q3 2026
- Soleus Capital Management, L.P. 246.35K sh · $15.75M · Q2 2026
- ESSEX INVESTMENT MANAGEMENT CO LLC 202.02K sh · $15.07M · Q3 2026
- ArrowMark Colorado Holdings LLC 215.55K sh · $13.78M · Q2 2026
- STEMPOINT CAPITAL LP 209.23K sh · $13.38M · Q2 2026
More on SILVERARC CAPITAL MANAGEMENT, LLC
FAQ
How long has SILVERARC CAPITAL MANAGEMENT, LLC held KNSA?
SILVERARC CAPITAL MANAGEMENT, LLC has disclosed KNSA holdings in 4 of the last 7 reported quarters, going back to Q1 2025.
What is SILVERARC CAPITAL MANAGEMENT, LLC's current position in KNSA?
As of Q3 2026, SILVERARC CAPITAL MANAGEMENT, LLC holds 75.70K shares of KNSA (KINIKSA PHARMACEUTICALS INTL), valued at $5.65M, representing 0.72% of its reported portfolio and ranking #36.
Has SILVERARC CAPITAL MANAGEMENT, LLC been buying or selling KNSA?
In the latest 13F filing (Q3 2026), SILVERARC CAPITAL MANAGEMENT, LLC newly opened its position in KNSA. The position peaked in Q3 2026 at 75.70K shares.
Which other funds hold KNSA?
Other major institutional holders of KNSA include Rubric Capital Management LP, BAKER BROS. ADVISORS LP, TANG CAPITAL MANAGEMENT LLC, among 51 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.